Startups
MinervaX
https://minervax.comDeveloper of prophylactic vaccine against Group B Streptococcus.
Summary
Industry
Insights
MinervaX, based in Copenhagen, is advancing the biotech field by developing a prophylactic vaccine against Group B Streptococcus (GBS) infections. This focus positions it as a key player in prenatal health, addressing risks of neonatal infections currently managed through screening and antibiotics. By prioritizing vaccine development, MinervaX aims to offer a more effective and less intrusive solution. The company's B2B model, along with backing from investors like EQT Partners and Novo A/S, showcases its potential for medical advancement and commercial success. If successful, MinervaX could revolutionize prenatal care, leading to widespread adoption and significant market impact.
Total Funding
$176M
- Debt Financing (2022) $53.3M
- Series C (2023-11-01) $57.3M
- Series B (2020-01-01) $58.0M
- Unknown (2019-01-01) $5.0M
- Seed (2014-08-01) $3.1M
Investors
European Investment Bank Debt Financing
Pureos Bioventures Series C
EQT Partners Series C
OrbiMed Series C
Industrifonden Series B
Wellington Partners Series B
Novo A/S Seed
Novo A/S Seed
Sunstone Life Science Ventures Seed
Vaekstfonden Seed
Full Company Profile
- Access details of the company management, and other intelligence on this company by registering for Seedtable